ICYMI, this week we had stories about managing Merkel cell carcinoma in patients with skin of color, addressing disparities in atopic dermatitis with telehealth, ruxolitinib for rapid pruritus reduction, and more.
The clinical presentations of Merkel cell carcinoma in patients with skin of color require dermatology providers to be more aware of the nuances in diagnosis and management.
The goal of a January 5, 2024, PDUFA date for berdazimer gel, 10.3%, continues with pre-approval inspection already complete.
In a study, researchers found that after 4 weeks of regular use, shampoo containing salicylic acid, urea, and glycerin significantly reduced Psoriasis Scalp Severity Index.
The aesthetic medical technology company announced that its hair regrowth system will be used in a second study.
In a Dermatology Times DermView custom video series, Shawn Kwatra, MD, and Peter Lio, MD, discuss the topical treatment landscape of atopic dermatitis.
Co-founders Jeff DeVico and Patrick DePippo discuss their app, ReachRX, which aspires to transform the dermatology and medical landscape through streamlined access to pharmaceutical information.
As a parent of a child with a vascular anomaly, Kumar has experienced all the emotions of having a child who is born with a skin condition.
If approved, hidradenitis suppurativa would be the 4th indication for the drug within the European Union.
Jemima Mellerio, MD, said a correct diagnosis often requires a lot of testing, questioning, and observation.
Adam Friedman, MD, FAAD, and Andrew Alexis, MD, MPH, discuss disparities in atopic dermatitis and the ways these can be addressed with teledermatology.
Researchers conducted a subgroup analysis of the ALLEGRO phase 2b/3 clinical trial to evaluate the safety and efficacy of the drug in patients aged 12-17.
Children of mothers who took more than 5 courses of antibiotics during pregnancy were at the highest risk.
Click here to answer this week's poll.
Men have a lower overall survival rate than women when diagnosed with melanoma.
Researchers anticipate that upwards of 10,000 adults with various dermatologic conditions will partake in the study.
Clinicians James Q. Del Rosso, DO; Raj Chovatiya, MD, PhD; and Lisa Swanson, MD, PhD, review the study, “Rapid Pruritus Reduction With Ruxolitinib Cream in Patients With Atopic Dermatitis."
Researchers conducted a systematic review and meta-analysis of probiotic treatment efficacy in children with atopic dermatitis.
In a recent study, authors argue that psychosocial impacts should be at the forefront of the discussion in acne scarring, noting that psychopharmacological management may be necessary in instances of severe psychiatric comorbidities.
The Melanoma Research Alliance provides funding to support investigators in preventing, detecting, and treating melanoma.
The women, aged 40 to 75, showed statistical improvement in firmness, lines and wrinkles, and crepiness.
Introducing our newest weekly series, the Journal Digest, a collection of trending studies from leading dermatology journals. This week’s first edition covers IVIg treatment for autoimmune bullous dermatoses, body-focused repetitive behaviors, hormonal treatments for HS, dupilumab and skin barrier function, and a 2023 alopecia areata update.
Compared to patients who identified as heterosexual, patients in the LGBTQ+ community have a higher prevalence of atopic dermatitis, asthma, and allergic rhinitis.
Study results are expected to be presented at international dermatology conferences by the end of the year.
A recent study found no correlation between a genetic predisposition to psoriasis or systemic treatment for psoriasis and an increase in the severity of COVID-19 illness.
Grant applications are open from now until August 24, 2023, with an anticipated project start/end date of January 2024 through July 2025.
Researchers applied EB-101, a new cell therapy, to patients with recessive dystrophic epidermolysis bullosa with positive results.